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Background: The progression and complications of chronic kidney disease should differ depending on the cause (C),
glomerular filtration rate category (G), and albuminuria (A). The KNOW-CKD (KoreaN Cohort Study for Outcome in
Patients With Chronic Kidney Disease), which is a prospective cohort study, enrolls subjects with chronic kidney
disease stages 1 to 5 (predialysis).
Methods/Design: Nine nephrology centers in major university hospitals throughout Korea will enroll approximately
2,450 adults with chronic kidney disease over a 5-year period from 2011 to 2015. The participating individuals will be
monitored for approximately 10 years until death or until end-stage renal disease occurs. The subjects will be classified
into subgroups based on the following specific causes of chronic kidney disease: glomerulonephritis, diabetic
nephropathy, hypertensive nephropathy, polycystic kidney disease, and others. The eligible subjects will be
evaluated at baseline for socio-demographic information, detailed personal/family history, office BP, quality of life,
and health behaviors. After enrollment in the study, thorough assessments, including laboratory tests, cardiac
evaluation and radiologic imaging, will be performed according to the standardized protocol. The biospecimen
samples will be collected regularly. A renal event is defined by >50% decrease in estimated GFR (eGFR) from the
baseline values, doubling of serum creatinine, or end-stage renal disease. The primary composite outcome consists
of renal events, cardiovascular events, and death. As of September 2013, 1,470 adult chronic kidney disease subjects
were enrolled in the study, including 543 subjects with glomerulonephritis, 317 with diabetic nephropathy, 294 with
hypertensive nephropathy and 249 with polycystic kidney disease.
Discussion: As the first large-scale chronic kidney disease cohort study to be established and maintained longitudinally
for up to 10 years, the KNOW-CKD will help to clarify the natural course, complication profiles, and risk factors of Asian
populations with chronic kidney disease.
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Chronic kidney disease (CKD) is a rapidly growing dis-
ease worldwide. The prevalence of CKD in Korea is
estimated to be 13% in the adult population [1]. Approxi-
mately 5% of the Korean adult population is estimated to
have decreased renal function with an estimated glomeru-
lar filtration rate (eGFR) less than 60 ml/min per 1.73 m2
[1]. CKD, which leads to dialysis or kidney transplantation,
presents a major threat to cardiovascular (CV) events
and all-cause mortality [2,3]. A patient with CKD is more
likely to die of CV disease than to start renal replacement
therapy.
Since 2002, a large number of epidemiologic studies,
in addition to the general population, have demonstrated
a significantly increased risk of adverse consequences in
subjects with albuminuria, even in the presence of nor-
mal or mildly decreased GFR [4,5]. This finding warrants
a broader view of the early stages of CKD within the
nephrology population to determine the variables associ-
ated with CKD and the increased risks of death and
adverse outcomes [6]. However, the mechanistic link be-
tween albuminuria and adverse consequences has not
been established.
Kidney Disease: Improving Global Outcomes (KDIGO)
2012 Clinical Practice Guideline for the Evaluation and
Management of CKD recommends a new classification
of CKD, based on the cause, GFR category, and albumin-
uria (CGA) [7]. The characteristics of CKD differ signifi-
cantly depending on the underlying disease or the location
of the pathologic-anatomic abnormalities. Therefore, we
hypothesized that the progression and complications of
CKD should be different among the disease subgroups,
which cause CKD. A new perspective in the viewpoint of
the “CGA” paradigm is required to analyze and interpret
the various parameters associated with CKD.
Nevertheless, recently established CKD cohort studies
[8-11] are primarily based on the CKD population with
low GFR (less than 60 ml/min per 1.73 m2). The above
studies targeted the cardiovascular complications from
subjects with moderate or severe renal impairment. In
these studies, the early stages of renal injury are ex-
cluded from their target population and the specific
causes of CKD are not considered. In contrast, a new
CKD cohort study, including all of the stages of the pre-
dialysis CKD population and considering the specific
causes of CKD, may lead us to gain insight into under-
standing the natural progression of CKD and the associ-
ation between CKD and CV outcomes or mortality.
The KNOW-CKD (KoreaN Cohort Study for Outcome
in Patients With Chronic Kidney Disease), funded by
the Korea Centers for Disease Control and Prevention
(KCDC), was established in 2011 by a group of nephrolo-
gists, epidemiologists, biostatisticians, and clinical patholo-
gists in Korea.The goals of the KNOW-CKD are as follows: 1) to es-
tablish an adult pre-dialysis CKD cohort covering the
early stages of CKD, as well as the advanced stages of
CKD, 2) to investigate the natural history of CKD, such
as renal progression, death, and complications with re-
spect to the CGA categories, 3) to evaluate the etiologic
factors for renal progression and related complications,
4) to identify the mechanistic link between renal injury and
adverse outcomes, and 5) to identify the genetic and mo-
lecular influences on renal progression and complications.
In the present paper, we report our study design and
methods and results from study participants registered
from 2011 to 2013.
Methods/Design
Organization
The KNOW-CKD is a patient-based cohort study. Ne-
phrologists working in nine clinical centers in the major
university-affiliated hospitals and epidemiologists, patholo-
gists and biostatisticians in a research modulating center
are participating in this study. The basic protocol of the
study was approved by the ethical committee of each par-
ticipating center including Institutional Review Boards of
Seoul National University Hospital, Severance Hospital,
Kangbuk Samsung Medical Center, Seoul St. Mary’s
Hospital, Gil Hospital, Eulji General Hospital, Chonnam
National University Hospital and Pusan Paik Hospital.
Among the nine clinical centers, six centers are located
in the metropolitan city of Seoul, one in a satellite area of
Seoul, Gyeonggi-do (a province), and two in the southern
area of Korea (i.e., Chonnam-do and Busan). Throughout
the national health care system, Korea has 44 tertiary-
care general hospitals. The distribution of our participat-
ing clinical centers is parallel to the distribution of the
major hospitals in Korea. The study is supervised by the
CKD Advisory Committee, which comprises members
from the KCDC and the Korean Society of Nephrology
(KSN) (NCT01630486 at http://www.clinicaltrials.gov).
Study population
Each participating center will enroll approximately 250
consecutive individuals over a 5-year period from 2011
until 2015, totaling 2,450 adult patients with CKD who
provide written informed consent. The participating in-
dividuals will be monitored for approximately 10 years
until death or until ESRD occurs.
The KNOW-CKD will enroll ethnic Korean patients
with CKD who range in age between 20 years and 75 years.
The CKD stages from 1 to 5 (predialysis), based on the
eGFR, is calculated using the four-variable Modification of
Diet in Renal Disease (MDRD) equation as follows:
eGFR (ml/min per 1.73 m2) = 175 × [serum Cr
(mg/dl)] -1.154 × [age]-0.203 × [0.742 if female] × [1.212 if
black], using serum creatinine concentrations measured
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national reference material [12].
Excluded subjects are those who 1) are unable or un-
willing to give written consent, 2) have previously re-
ceived chronic dialysis or organ transplantation, 3) have
heart failure (NYHA class 3 or 4) or liver cirrhosis
(Child-Pugh class 2 or 3), 4) have a past or current his-
tory of malignancy, 5) are currently pregnant, or 6) have
a single kidney due to trauma or kidney donation.
We defined and allocated the specific causes of the
CKD into four subgroups: glomerulonephritis (GN),
diabetic nephropathy (DN), hypertensive nephropathy
(HTN), and polycystic kidney disease (PKD). The defin-
ition of the subgroup is defined by the pathologic diag-
nosis, in the event that the biopsy result is available.
Otherwise, the subgroup classification depends on the clin-
ical diagnosis. GN is defined by the presence of glomerular
hematuria or albuminuria with or without an underlying
systemic disease causing glomerulonephritis. The diagnosis
of DN is based on albuminuria in a subject with type 2 dia-
betes mellitus and the presence of diabetic retinopathy.
HTN is defined by the patient’s hypertension history and
the absence of a systemic illness associated with renal dam-
age. Unified ultrasound criteria [13] will be used to diag-
nose PKD. The other causative diseases will be categorized
as ‘unclassified’.
Data collection
The detailed protocol for data and sample collection is
described in Table 1. The eligible subjects will be
screened and evaluated at baseline for socio-demographic
information, smoking, alcohol consumption, medication,
and detailed personal and family medical histories. The an-
thropometric measurements (height, weight, and waist/hip
ratios), and measurements of the resting blood pressure
(BP) in the clinic and pulse pressure using an electronic
sphygmomanometer will be conducted. The subjects will
complete questionnaires concerning quality of life, socio-
economic status, educational level, physical activity, health
behaviors, and health care facility utilization. After enroll-
ment in the study, the laboratory tests, cardiac evaluation
and radiologic imaging will be performed according to the
specific protocol. DNA, serum and urine samples will be
initially collected. Serum and urine samples will be subse-
quently collected on a regular basis according to the stan-
dardized protocol. The details regarding the study visit and
test schedule are shown in Table 1.
All of the data, including clinical information, la-
boratory results and outcome, will be entered into a
web-based, electronic, case-reporting form (eCRF). The
electronic data management system for the KNOW-CKD
was developed by the division of data management in
Seoul National University Medical Research Collaborating
Center.Outcome variables
A renal event is defined by a >50% decrease in eGFR
from the baseline values, doubling of serum creatinine,
or ESRD. The estimated GFR for defining renal outcome
will be based on the four-variable MDRD formula. How-
ever, the Chronic Kidney Disease Epidemiology Collabor-
ation (CKD-EPI) creatinine equation [14] or the CKD-EPI
creatinine-cystatin C equation [15] will also be employed
to estimate GFR.
At each visit, the subjects will be queried and evaluated
for CV events, including myocardial infarction (fatal and
nonfatal), coronary revascularization, stroke and new onset
or aggravation of congestive heart failure. The causes of
death will be verified and classified as cardiac, non-cardiac
and unknown. An independent committee will adjudicate
all of the primary outcomes. The subjects who withdraw
from the study will be traced for this type of information
with the help of the National Health Insurance System and
Korea Statistical Information Service. The secondary out-
comes are hospitalization, fracture, QOL, and economic
status during the follow-up.
Biospecimen collection
Using an EDTA tube, 3 ml of whole blood will be ob-
tained and sent immediately for extracting DNA to the
central laboratory. Another 10 ml of whole blood will
be obtained using the serum separation tube (SST) and
centrifuged within 1 hour for serum separation and
sent to the central laboratory for measurements of cre-
atinine, cystatin C, intact parathyroid hormone (iPTH),
25-hydroxyvitamine D3 (25D), 1,25-dihydroxyvitamin
D3 (1,25D), and troponin T. Serum creatinine will be
measured using an IDMS-traceable method; and cysta-
tin C will be calculated using immunonephelometry
calibrated against the reference material [15-17]. The
first-voided urine samples (15 ml) will be collected for
assaying albumin, protein, calcium (Ca), phosphorus (P),
urea, uric acid, electrolytes and osmolality at the central
laboratory. The aliquots of the remaining serum and
urine samples will be stored in a deep freezer (−70°C) in
two different places for future studies. Stringent rules for
the sample harvest and processing will be applied to en-
sure accurate assays. Blood and urine sampling will be
conducted under strict monitoring guidelines throughout
the study period.
Follow-up
The participating subjects will visit the center ac-
cording to the follow-up schedule. At each visit, the
subjects will undergo scheduled tests; the investiga-
tors will review the subjects’ recent medical histories
and occurrence of events. We assumed that 10% of
the individuals would withdraw from the study and
that ESRD or death would develop subsequently in
Table 1 Schedule of the KNOW-CKD at each visit
Parameter
Visit time (year)
Screening Baseline 0.5 1 2 3 4 5 6 7 8 9 10
Informed consent O
Demographic information O
Medical History O
Eligibility confirmation O
Recent events O O O O O O O O O O O
Medications O O O O O O O O O O O O
Health Questionnaires O O
KDQOL questionnaires O O
Blood pressure O O O O O O O O O O O O
Anthropometry O O O O O O O O O O O O
CBC, chemistry O O O O O O O O O O O O
IDMS-traceable Cr, MDRD eGFR O O O O O O O O O O O O
Cystatin C O O O O O O O O O O O O
HbA1c (diabetic subjects) O O O O O O O O O O O O
Lipid panel, CRP, iron profile O O O O O O
Intact PTH, 25D, 1,25 D, cardiac troponin T O O O O O O
Urinalysis O O O O O O O O O O O O
24-h urine collection O O O O O
Electrolyte/Cr/osmolality, albumin/protein (Spot urine) O O O O O O
Electrocardiogram, chest X ray O O O O O O
Echocardiography, Pulse wave velocity, Ankle-brachial index, MDCT,
LS spine lateral X-ray for vascular calcification
O O O
Bone mineral density O O O O
DNA sample O
Plasma/urine sample O O O O O O O O O O O O
Fundus exam (diabetic subjects) O
Abdomen CT or MRI (polycystic kidney disease) O O O O O O
Family screen (polycystic kidney disease) O
CBC, complete blood count; KDQOL, Kidney Disease –Quality of Life; IDMS-serum cr, serum creatinine measurement using IDMS-traceable method; MDCT, multidetector
computed tomography for coronary calcium score.
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made to prevent drop-outs, i.e., providing free med-
ical examinations, frequent telephone calls and diet-
ary education.Institutional review board (IRB) approval
The study protocol was approved by the IRB at each
participating clinical center in 2011.Statistical power estimation
With an overall sample size of 600 subjects, which is the
size of the each subgroup (GN, DN, HTN, and PKD),
80% power is achieved to detect hazard ratios of ap-
proximately 2.00 and 1.60 for an exposure with preva-
lence of 0.1 and 0.5 and a dropout rate of 10%.Statistical methods and plan
The baseline characteristics of the study participants for
each subgroup were presented with descriptive statistics
using a one-way analysis of variance or Kruskal-Wallis
test according to the distribution of continuous variables
and a chi-square test or Fisher’s exact test for categorical
variables.
To analyze the association of outcome variables, the
time-to-event analysis will be used to evaluate primary out-
comes, such as renal events (initiation of renal replacement
therapy and 50% decline of GFR), CV events (myocardial
infarction and ischemic stroke) and death. The Kaplan-
Meier curves and the proportional hazard models will serve
as major statistical methods for the outcomes. The inci-
dence or mortality rates according to each outcome vari-
able will be calculated for each etiologic group; the
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betic nephropathy subgroup. The effect of exposure on the
development of outcomes will be analyzed separately in
each group and in the overall groups. The heterogeneity of
each relative risk within the KNOW-CKD subcohort will
be analyzed using the Cochran Q test or using a shared-Table 2 General characteristics of study subjects participating
Total cohort1
GN
Total participants from 2011 to 2013 1470 543
Age 53.6 ± 12.3 50 ± 12
Female 569 (38.7) 228 (4
BMI (kg/m2) 24.4 ± 3.4 24.2 ± 3
Waist-Hip ratio 0.89 ± 0.07 0.88 ± 0
SBP (mmHg) 127.7 ± 16.5 123.2 ± 1
DBP (mmHg) 76.6 ± 11.1 75.2 ± 1
Pulse Pressure (mmHg) 51.1 ± 12.1 48 ± 10
CKD stage 1 160 (10.9) 81 (14.
2 253 (17.2) 117 (21
3a 268 (18.2) 111 (20
3b 328 (22.3) 110 (20
4 349 (23.7) 93 (17.
5 112 (7.6) 31 (5.7
Creatinine (mg/dL) 1.88 ± 1.17 1.67 ± 1
Cystatin C (mg/L) 1.81 ± 0.95 1.61 ± 0
eGFR (mL/min/1.73 m2)
MDRD 48.6 ± 29.4 54.9 ± 3
CKD-EPI cr (2009) 51.4 ± 30.3 58.3 ± 3
Comorbid disease
Coronary artery disease 107 (7.3) 22 (4.1
Peripheral vascular disease 22 (1.5) 2 (0.4
Cerebrovascluar disease 125 (8.5) 21 (3.9
Diabetes 462 (31.6) 56 (10.
Hypertension 1325 (90.6) 470 (86
Chronic heart failure 15 (1) 3 (0.6
Arrhythmia 31 (2.1) 8 (1.5
Cardiac parameters
AAC score 1.2 ± 2.6 0.7 ± 1
Mean baPWV (cm/s) 1525.0 ± 342.5 1396.4 ± 2
LVMI (g/m2) (Echocardiography) 95.0 ± 28.4 89.5 ± 2
Coronary Ca score 191.7 ± 569.6 91.6 ± 40
Troponin T (ng/mL) 0.016 ± 0.018 0.011 ± 0
Valve calcification (Echocardiography) 262 (18.5) 105 (20
1Total participants included those in 4 subgroups and the other unclassified kidney
ANOVA or Kruskal-Wallis test for continuous variables and Chi-square or Fisher’s Exa
Numbers denote mean ± s.d. or number (%).
Abbreviations: GN, glomerulonephropathy; DN , diabetic nephropathy; HTN, hyperte
kidney disease; AAC, abdominal aorta calcification; baPWV, brachial-to-ankle pulse wfrailty model, where time-dependent confounders should
be adjusted [19]. The CKD progression will be evaluated
using decreased GFR calculations. Because it is common
for a patient with CKD to have a non-linear decline in GFR
or a prolonged period of non-progression [20], we will as-
sess the longitudinal trajectory of GFR for the individualin KNOW-CKD from 2011 to September, 2013
Subcohort
DN HTN PKD p-value2
317 294 249
.3 59.2 ± 9.3 59.6 ± 10.9 46.9 ± 10.4 < 0.001
2) 104 (32.8) 82 (27.9) 127 (51) < 0.001
.4 25.2 ± 3.2 24.8 ± 3.5 23.5 ± 3.1 < 0.001
.07 0.92 ± 0.05 0.9 ± 0.07 0.88 ± 0.06 < 0.001
4.9 135.8 ± 18.7 127 ± 16.4 128 ± 13.5 < 0.001
0.6 76.1 ± 11.8 76.8 ± 11.6 79.8 ± 10.2 < 0.001
.6 59.7 ± 12.9 50.2 ± 11.5 48.2 ± 9.5 < 0.001
9) 4 (1.3) 2 (0.7) 63 (25.3) < 0.001
.5) 18 (5.7) 18 (6.1) 79 (31.7)
.4) 45 (14.2) 67 (22.8) 35 (14.1)
.3) 83 (26.2) 91 (31) 30 (12)
1) 121 (38.2) 95 (32.3) 30 (12)
) 46 (14.5) 21 (7.1) 12 (4.8)
.08 2.48 ± 1.38 2.12 ± 1.00 1.40 ± 0.98 < 0.001
.89 2.37 ± 0.99 2.04 ± 0.83 1.34 ± 0.79 < 0.001
0.6 32.7 ± 17.9 36.6 ± 17.4 67 ± 33.9 < 0.001
1 34 ± 19.5 37.9 ± 17.7 71.8 ± 33.6 < 0.001
) 44 (14.1) 32 (10.9) 3 (1.2) < 0.001
) 10 (3.2) 9 (3.1) 0 (0) < 0.001
) 37 (11.9) 34 (11.6) 29 (11.6) < 0.001
4) 317 (100) 61 (20.7) 3 (1.2) < 0.001
.9) 302 (96.8) 283 (96.3) 213 (85.5) < 0.001
) 8 (2.6) 4 (1.4) 0 (0) 0.011
) 6 (1.9) 12 (4.1) 3 (1.2) 0.049
.9 2.6 ± 3.7 1.3 ± 2.7 0.3 ± 1.3 < 0.001
45.8 1819.2 ± 418.2 1569.1 ± 297.7 1392 ± 213.2 < 0.001
5.2 106.5 ± 30.7 100.6 ± 31.9 85.9 ± 20.1 < 0.001
9.9 496.3 ± 864.6 195.6 ± 569.5 28.5 ± 133.1 < 0.001
.010 0.030 ± 0.030 0.016 ± 0.011 0.008 ± 0.004 < 0.001
.2) 82 (27.1) 65 (23) 7 (2.8) < 0.001
diseases.
ct test for categorical variables.
nsive nephropathy; PKD, autosomal dominant polycystic
ave velocity; LVMI, left ventricular mass index.
Table 3 General characteristics of study participants according to CKD stage, KNOW-CKD from 2011 to September, 2013
CKD Stage1
Stage 1 Stage 2 Stage 3a Stage 3b Stage 4 Stage 5 p-value2
Total participants from 2011 to 2013 160 253 269 328 350 112
Age 42.2 ± 11.8 49.6 ± 11.9 54.8 ± 11.7 56.7 ± 10.7 57.5 ± 11 54.5 ± 11.6 < 0.001
Female 82 (51.3) 92 (36.4) 79 (29.4) 126 (38.4) 133 (38) 57 (50.9) < 0.001
Height (cm) 165.4 ± 8.0 166.3 ± 8.5 165.3 ± 8.2 163.5 ± 8.1 164.1 ± 8.3 162.0 ± 8.8 < 0.001
Weight (kg) 64.9 ± 12.8 68.0 ± 12.5 67.6 ± 11.5 66.3 ± 10.5 65.8 ± 11.4 63.6 ± 12.1 0.005
BMI (kg/m2) 23.6 ± 3.7 24.5 ± 3.5 24.7 ± 3.3 24.8 ± 3.2 24.4 ± 3.3 24.2 ± 3.5 0.001
Waist-Hip ratio 0.87 ± 0.06 0.88 ± 0.07 0.89 ± 0.07 0.91 ± 0.07 0.91 ± 0.06 0.89 ± 0.06 < 0.001
SBP (mmHg) 126.3 ± 15.6 126.1 ± 16.1 126.3 ± 15.3 126.1 ± 15.3 129.4 ± 17.3 136.1 ± 19.8 < 0.001
DBP (mmHg) 77.6 ± 10.9 77.2 ± 11.9 76.6 ± 10.1 75.5 ± 10.4 76.1 ± 11.7 78.7 ± 11.8 0.275
Pulse Pressure (mmHg) 48.7 ± 10 48.9 ± 10.3 49.7 ± 11.8 50.5 ± 12.3 53.3 ± 12.5 57.4 ± 14.2 < 0.001
Urine ACR (mg/g cr) < 0.001
A1 (< 30) 53 (34.4) 71 (29.6) 41 (16.3) 37 (12.1) 15 (4.5) 2 (1.9)
A2 (30 ~ 300) 47 (30.5) 76 (31.7) 86 (34.3) 110 (35.8) 98 (29.5) 20 (18.5)
A3 (300≤) 54 (35.1) 93 (38.7) 124 (49.4) 160 (52.1) 219 (66) 86 (79.6)
Primary kidney disease < 0.001
GN 81 (51) 117 (46) 111 (41) 110 (34) 93 (27) 31 (28)
DN 4 (3) 18 (7) 45 (17) 83 (25) 121 (35) 46 (41)
HTN 2 (1) 18 (7) 67 (25) 91 (28) 95 (27) 21 (19)
PKD 63 (39) 79 (31) 35 (13) 30 (9) 30 (9) 12 (11)
Unclassified 10 (6) 21 (8) 11 (4) 14 (4) 11 (3) 2 (2)
Comorbid disease
Coronary artery disease 4 (2.5) 7 (2.8) 24 (9) 30 (9.2) 36 (10.4) 6 (5.4) < 0.001
Peripheral vascular disease 1 (0.6) 2 (0.8) 4 (1.5) 1 (0.3) 13 (3.7) 1 (0.9) 0.010
Cerebrovascluar disease 4 (2.5) 13 (5.2) 29 (10.9) 30 (9.2) 40 (11.5) 9 (8.1) 0.004
Diabetes 19 (11.9) 46 (18.3) 73 (27.3) 118 (36.3) 156 (45) 50 (45) < 0.001
Hypertension 126 (78.8) 217 (86.1) 241 (90.3) 305 (93.8) 331 (95.4) 105 (94.6) < 0.001
Congestive heart failure 0 (0) 0 (0) 1 (0.4) 3 (0.9) 10 (2.9) 1 (0.9) 0.007
Arrhythmia 1 (0.6) 5 (2) 8 (3) 8 (2.5) 7 (2) 2 (1.8) 0.701
Creatinine (mg/dL) 0.71 ± 0.14 1.00 ± 0.18 1.33 ± 0.18 1.75 ± 0.27 2.68 ± 0.61 4.75 ± 1.36 < 0.001
Cystatin C (mg/L) 0.76 ± 0.15 1.00 ± 0.20 1.33 ± 0.24 1.76 ± 0.33 2.60 ± 0.52 3.89 ± 0.70 < 0.001
eGFR (mL/min/1.73 m2)
MDRD 109.4 ± 20.2 73 ± 8.6 52.1 ± 4.4 37 ± 4.2 23.2 ± 4.3 11.8 ± 2.3 < 0.001
CKD-EPI cr (2009) 110.9 ± 10.4 80.7 ± 10.9 55.8 ± 5.5 38.9 ± 4.8 23.8 ± 4.7 11.9 ± 2.5 < 0.001
Hemoglobin (g/dL) 14 ± 1.4 13.9 ± 1.7 13.5 ± 1.8 12.8 ± 1.8 11.7 ± 1.5 10.6 ± 1.2 < 0.001
P (mg/dL) 3.5 ± 0.6 3.5 ± 0.6 3.5 ± 0.5 3.6 ± 0.6 3.9 ± 0.6 4.7 ± 0.7 < 0.001
hsCRP (mg/L) 1 ± 2.3 1.8 ± 3.9 2.2 ± 6.4 1.7 ± 3 3.1 ± 8.1 1.9 ± 3.8 < 0.001
Intact PTH (pg/mL) 40.2 ± 17.7 38.8 ± 14.2 53.2 ± 30.2 55.7 ± 21 92.4 ± 41.8 220 ± 118.3 < 0.001
25D (ng/mL) 15.8 ± 4.8 18.9 ± 6.7 19.3 ± 7.7 18.7 ± 7.3 18.2 ± 8.2 17.1 ± 7.8 < 0.001
1,25D (pg/mL) 30.5 ± 7.6 30.8 ± 7.3 28.5 ± 7.5 26.9 ± 5.8 23.5 ± 5.3 24.7 ± 7.4 < 0.001
Cardiac parameters
Mean baPWV (cm/s) 1313.4 ± 189.3 1419.4 ± 239.4 1502 ± 303.6 1587 ± 329.4 1637 ± 417.6 1629.8 ± 369.2 < 0.001
LVMI (g/m2) (Echocardiography) 85.5 ± 23 86.2 ± 23.1 89.9 ± 23.9 96.1 ± 25.2 104.1 ± 31.2 109.6 ± 39.6 < 0.001
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Table 3 General characteristics of study participants according to CKD stage, KNOW-CKD from 2011 to September, 2013
(Continued)
Coronary Ca score 44.2 ± 225.7 101.1 ± 313.1 230.7 ± 705.3 219.5 ± 599.1 252.9 ± 634.9 241.9 ± 644.6 < 0.001
Troponin T (ng/mL) 0.006 ± 0.003 0.008 ± 0.004 0.011 ± 0.006 0.016 ± 0.015 0.024 ± 0.024 0.031 ± 0.030 < 0.001
Valve calcification (Echocardiography) 12 (7.6) 31 (12.6) 39 (15.3) 75 (23.5) 75 (22.5) 30 (28) < 0.001
1CKD stage classified by MDRD equation.
ANOVA or Kruskal-Wallis test for continuous variables and Chi-square or Fisher’s Exact test for categorical variables.
Numbers denote mean ± s.d. or number (%).
Abbreviations: GN, glomerulonephropathy; DN, diabetic nephropathy; HTN, hypertensive nephropathy; PKD, autosomal dominant polycystic kidney disease;
baPWV, brachial-to-ankle pulse wave velocity; LVMI, left ventricular mass index.
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http://www.biomedcentral.com/1471-2369/15/80participants of KNOW-CKD using the Bayesian smoothing
technique [21]. If the progression of CKD is steady and lin-
ear, the generalized estimating equation will be adopted to
compare the slope of the GFR with repeated measure-
ments. The progression of CKD will be supplemented with
an event-based analysis, whereby the occurrence of ESRD
or the substantial decrease of GFR will be treated as the
events of interest.
Results on interim analysis
From July 2011 to September 2013, we enrolled 1,470 par-
ticipants, including 543 GN, 317 DN, 294 HTN, 249 PKD
sub-participants and remaining participants with unclassi-
fied subtypes. The baseline demographics and the labora-
tory values of KNOW-CKD are summarized in Tables 2
and 3. The mean age of the total CKD cohort at the time of
study enrollment is 53.6 ± 12.3 years, 38.7% are female, and
31.6% diabetic. The proportion of each CKD stage is as fol-
lows; 10.9% (stage 1), 17.2% (stage 2), 18.2% (stage 3a),
22.3% (stage 3b), 23.7% (stage 4) and 7.6% (stage 5, nondia-
lyzed). GN, DN, HTN and PKD were the most common
causative diseases in descending order. At baseline, 7.3% of0%
50%
100%
Total GN DN
Figure 1 Age-adjusted modified Charlson comorbidity index in total
GN, glomerulonephritis; DN, diabetic nephropathy; HTN, hypertensive nephthe cohort had a history of coronary heart disease, 8.5%
had cerebrovascular disease, and 90.6% had hypertension.
In terms of the Charlson comorbidity score and various
cardiac parameters, the DN subgroup exhibited the worst
profiles (Figure 1 and Table 2). In subjects with advanced
CKD stages, the elevated levels of pulse pressure, serum
phosphorus, and intact PTH were more pronounced than
the subjects with early stages. Hemoglobin levels, 25D and
1,25D, were significantly lower and the left ventricular mass
index (LVMI), coronary calcium score and valve calcifica-
tion were higher in subjects with advanced CKD stages.
Discussion
The prevalence of CKD is increasing, as are the risk factors
for CKD, such as diabetes, metabolic syndrome, and hyper-
tension [22]. The National Health and Nutrition Examin-
ation Survey (NHANES) data from the U.S.A. show that
the prevalence of CKD increased from 10% in the 1994–
1998 cohort up to 13.1% in the 1999–2004 cohort [23].
CKD is a major risk factor for the development of cardio-
vascular complications and all-cause mortality. One large
observational study reported that the risk of death increasedHTN PKD
Low (≤3)
Moderate (4-5)
High (6-7)
Very high (≥8)
and subgroup participants, KNOW-CKD 2011–2013. Abbreviations:
ropathy; PKD, polycystic kidney disease.
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http://www.biomedcentral.com/1471-2369/15/80dramatically as the GFR decreased below 60 ml/min per
1.73 m2 [3]. The adjusted hazard ratio for death was 3.2; the
eGFR ranged from 15 ml/min to 29 ml/min per 1.73 m2.
In a recent meta-analysis of the general population co-
hort, including a total of more than one million individ-
uals [24], the risk of death was fairly constant at eGFR
of 75–105 ml/min per 1.73 m2. However, albuminuria,
which is the earliest marker of glomerular damage, was
independently associated with increased mortality, even
in the presence of normal GFR. This point emphasizes the
importance of albuminuria as a prognostic indicator, inde-
pendent of GFR stages. Therefore, unlike previous CKD
cohort studies, the KNOW-CKD included subjects with al-
buminuria or other early markers of kidney damage and
with normal or mildly decreased GFR (CKD stage 1 to 2),
as well as subjects with GFR < 60 ml/min per 1.73 m2
(CKD stages 3 to 5). The KNOW-CKD will also analyze
various outcomes of CKD based on the specific causes of
CKD and based on the GFR and albuminuria categories.
Many studies have shown that racial/ethnic disparities
exist in mortality and cardiovascular outcome among in-
dividuals with CKD [25-28]. Asian patients with CKD
generally have a lower burden of CV disease compared
with other racial groups. The KNOW-CKD, which is the
first large-scale cohort study with Korean patients with
CKD, aims to explore the course of renal progression
and CV events and to elucidate the risk factors for renal
or CV outcomes in Korean subjects with CKD.
The original MDRD Study equation [29], which was de-
veloped in 1999, was modified for creatinine assays trace-
able to the international reference material for creatinine
[12]. However, the accuracy and the precision of the MDRD
equation have been controversial issues, especially at higher
GFR. The CKD-EPI equation, which uses the same four
variables as the MDRD Study equation, has less bias than
the MDRD Study equation [14], especially at GFR > 60 ml/
min per 1.73 m2, and is suggested to be more accurate than
the MDRD formula in Asian populations. The KNOW-
CKD will employ the MDRD Study equation [12], as well
as the CKD-EPI creatinine [14] and the CKD-EPI
creatinine-cystatin C equations [15], to ensure the accuracy
of the GFR estimation. Creatinine and cystatin C assays will
be conducted in a central laboratory, using assay methods
traceable to the international reference materials [16,17].
The KNOW-CKD will evaluate the complication pro-
files of anemia and mineral-metabolic derangements
across the CKD stages. The KNOW-CKD will compare
the clinical manifestations and natural course of the fol-
lowing four major renal etiologic subgroups: GN, DN,
HTN, and PKD. Various biomarkers from the serum and
urine samples will be evaluated to determine the risk
prediction of adverse consequences. The genetic and
epigenetic factors will be targeted. The KNOW-CKD
will also evaluate the socio-economic burden and itsimpact on the quality of life, and the hospitalization of
patients with CKD. Comparing the KNOW-CKD with
other large-scale CKD cohorts through international col-
laboration may provide a platform for future research.
Conclusion
As the first large-scale CKD cohort study to be estab-
lished and maintained longitudinally for up to 10 years,
the KNOW-CKD will help to clarify the natural course,
complication profiles, and risk factors of Asian popula-
tions with CKD. Including subjects in the early stages of
CKD as well as those in the advanced stages and focus-
ing on the causes will permit insight into CKD.
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